Antibodies directed against ICOS and uses thereof

Patent metadata

Field	Value
Publication number	US-10745482-B2
Application number	US-201916533038-A
Country	US
Kind code	B2
Filing date	Aug 6, 2019
Priority date	Mar 31, 2011
Publication date	Aug 18, 2020
Grant date	Aug 18, 2020

Abstract

The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4− T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

First claim

The invention claimed is:

1. A method of treating cancer in a human in need thereof, the method comprising administering to the human an anti-ICOS antibody or antigen binding portion thereof that binds human ICOS, wherein the anti-ICOS antibody or antigen binding portion thereof
comprises a CDRH3 comprising the sequence set forth in SEQ ID NO: 9 or a CDRH3 comprising no more than one conservative amino acid substitution in the sequence set forth in SEQ ID NO: 9,
wherein the conservative amino acid substitution is substitution of an amino acid having one or more similar properties selected from: polarity, hydrogen bonding potential, acidity, basicity, hydrophobicity, and aromaticity, or
wherein the conservative amino acid substitution is tyrosine to serine or threonine.

2. The method of claim 1 , wherein the anti-ICOS antibody or antigen binding portion thereof blocks binding of ICOS-L to human ICOS.

3. The method of claim 1 , wherein the anti-ICOS antibody or antigen binding portion thereof reduces number and/or activity of Treg cells.

4. The method of claim 1 , wherein the anti-ICOS antibody is a monoclonal antibody.

5. The method of claim 1 , wherein the anti-ICOS antibody binds human ICOS with affinity of ED50<0.5 ug/ml.

6. The method of claim 1 , wherein the anti-ICOS antibody blocks ICOS-L binding to human ICOS with blocking potential of ID 50<1 mg/ml.

7. The method of claim 1 , wherein the cancer is selected from: ovarian cancer, cervical cancer, breast cancer, colon cancer, lung cancer, prostate cancer, head and neck cancer, pancreatic cancer, bladder cancer, colorectal cancer, kidney cancer, stomach cancer, skin cancer, and esophageal cancer.

Assignees

• Inserm (Institut National De La Sante Et De La Rech Medicale)
• Inst Jean Paoli & Irene Calmettes
• Univ Aix Marseille
• Univ Claude Bernard—Lyon 1
• Centre Leon Berard
• Institut National De La Sante Et De La Rech Medicale (Inserm)
• Univ D' Aix-Marseille

Inventors

• Faget Julien
• Caux Christophe
• Menetrier-Caux Christine
• Nunes Jacques
• Olive Daniel

Classifications

• G01N33/57515

  of the breast · CPC title

• A61P11/06

  Antiasthmatics · CPC title

• A61P17/06

  Antipsoriatics · CPC title

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title